Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) plus pembrolizumab (pembro) plus carboplatin (carbo) +/- bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC)
No Thumbnail Available
Date
2022
Authors
Vergote, Ignace
Mirza, Mansoor Raza
Sehouli, Jalid
Lorusso, Domenica
Ose, Fatih K.
Cibula, David
Westermann, Anneke M.
Collins, Dearbhaile Catherine
Banerjee, Susana N.
Oaknin, Ana